Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sanjivani Paranteral Limited reported FY26 total income of ₹697.56 million with EBITDA of ₹114 million (16.34% margin) and PAT of ₹66.94 million (9.60% margin). Revenue from operations stood at ₹686.66 million, with tablets segment growing approximately 7.5% YoY to ₹279.14 million and injectables contributing ₹346.15 million (53.45% of revenue). Exports contributed 78.50% of revenue at ₹508 million, with core markets (CIS, Middle East & Africa, Latin America) accounting for 77.01%. The company highlighted commencement of commercial production at its new IV Fluid Infusion Plant in Pune as a key milestone. Q4 FY26 showed revenue of ₹132.13 million with EBITDA margin of 15.74% and PAT margin of 3.97%.
The company delivered healthy full-year profitability with 9.60% PAT margin and 16.34% EBITDA margin, supported by export-driven growth and new manufacturing capacity. The expansion into IV fluids positions the company for additional revenue streams in FY27.